Home › Lung Cancer › Pennsylvania › Pittsburgh
Lung Cancer clinical trials in Pittsburgh, PA
23 studies for Lung Cancer are looking for participants at sites in and around Pittsburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
RecruitingPhase 3
- Bryn Mawr Hospital, Bryn Mawr · 11 mi away
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
RecruitingPhase 1/2
- Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- and 11 more
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RecruitingPhase 3
- Bryn Mawr Hospital, Bryn Mawr · 11 mi away
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
Recruiting
- UPMC Hillman Cancer Center, Pittsburgh
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecruitingPhase 3
- UPMC Hillman Cancer Center, Pittsburgh
- Bryn Mawr Hospital, Bryn Mawr · 11 mi away
- UPMC Hillman Cancer Center - Monroeville, Monroeville · 11 mi away
- and 1 more
A Registry for People With Lung Cancer
RecruitingObservational study
- ALLEGHENY HEALTH NETWORK (Data Collection Only), Pittsburgh
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
RecruitingPhase 2
- Research Site, Pittsburgh
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RecruitingPhase 2/3
- West Penn Allegheny Health, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingPhase 1/2
- Allegheny Health Network, Pittsburgh
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
RecruitingPhase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- UPMC Hillman Cancer Center, Pittsburgh
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RecruitingPhase 3
- Allegheny Cancer Center, Pittsburgh
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
RecruitingPhase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
RecruitingPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RecruitingPhase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RecruitingPhase 2
- Allegheny General Hospital, Natrona Heights · 19 mi away
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RecruitingPhase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecruitingPhase 2
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- and 11 more
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2/3
- UPMC-Saint Margaret, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- and 9 more
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
RecruitingObservational study
- Allegheny Health Network, Pittsburgh
Detection of Genetic Markers of Lung Cancer
RecruitingObservational study
- Hillman Cancer Center, Pittsburgh
About Lung Cancer
Lung cancer forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women.
More about Lung Cancer on MedlinePlus
Lung Cancer trials in other cities
- Houston, TX78 studies
- Boston, MA62 studies
- New York City, NY60 studies
- Los Angeles, CA45 studies
- Arlington, VA41 studies
- Washington, DC41 studies
- Chicago, IL41 studies
- Nashville, TN40 studies
- Baltimore, MD40 studies
- St. Louis, MO39 studies
- Columbus, OH37 studies
- Philadelphia, PA36 studies
Other studies in Pittsburgh
- Non-Small Cell Lung Cancer48 studies
- Cancer (all types)41 studies
- Breast Cancer39 studies
- Colorectal Cancer32 studies
- Metastatic Cancer31 studies
- Melanoma31 studies
- Ovarian Cancer30 studies
- Endometrial Cancer23 studies
- Prostate Cancer23 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Stroke22 studies
- Depression22 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.